Specific lots of a popular ACE inhibitor are being recalled after a sample produced an out-of-specification test result. The FDA categorized this issue as a Class II recall. 

The newly approved device is 14% shorter than the previous version and gives clinicians more options when making implant decisions.

CMS just finalized significant changes to its TAVR coverage policies. Three leading cardiovascular health societies shared a joint statement summarizing their initial feedback. 

Multiple veteran cardiologists have been accused of accepting bribes from medtech companies. No arrests have been made at this time. 

TCT 2026 will include a full schedule of late-breaking studies focused on minimally invasive interventions, pharmaceutics, structural heart disease and much more.

Johnson & Johnson is selling key assets related to its Laminar program to a new startup, Jaguar LAA. This comes less than three years after Johnson & Johnson acquired Laminar for $400 million. 

Nearly 200 U.S. facilities were eligible for these rankings. Each one is either a freestanding children’s hospital or a large multidisciplinary pediatric department within a major medical center.

Clinicians have believed for years that menopause was responsible for a dramatic shift in pulse pressure that occurs in women as they age. According to a large new study, however, that change appears to occur years before menopause even begins. 

The ACCESS model is designed help more patients get treated and managed with advanced technologies. In addition to heart failure, improved coverage has been announced for Medicare beneficiaries battling COPD, substance use disorders and nicotine dependence.

Damodhar Suresh, MD, spoke to Cardiovascular Business about some of the biggest studies presented during the annual ESC conference in Munich, Germany.